热门资讯> 正文

Legend Biotech第三季度Carvykti的销售额为5.24亿美元

2025-10-14 20:32

Legend Biotech (NASDAQ:LEGN) said that it earned $524M in sales, based on preliminary data, for its multiple myeloma, T-cell therapy Carvykti (ciltacabtagene autoleucel) in Q3.
The net trade sales figure is based on information provided by Johnson & Johnson (JNJ) unit Janssen, Legend's partner on Carvykti.
Sales of Carvykti booked by Legend in Q3 2024 was ~$286M.
Legend is slated to report its Q3 financial results on Nov. 11.

More on Legend Biotech

Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
Legend Biotech Corporation 2025 Q2 - Results - Earnings Call Presentation
Legend Biotech, J&J ink Carvykti supply agreement
Legend Biotech considering second stock listing outside US

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。